Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience - Wikidata - wikimedia - TriplyDB

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

http://www.wikidata.org/entity/Q26995499

about

The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.Prospects for the use of ipilimumab in treating advanced prostate cancer.VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Immune Checkpoint Therapies in Prostate Cancer.Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis.Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities.Adverse Events in Cancer Immunotherapy.Ipilimumab for the treatment of metastatic prostate cancer.Immunotargeting and personalized therapies in genitourinary cancers.

P2860

Q26738677-62BB7EBF-AEE6-40FD-9B4F-3000A250A42A Q28553328-B51CC4B2-69C1-4FBF-A61E-E85DD40AFF75 Q36125878-C86D77B0-E52B-4DA9-BCFC-DDAD2D26A116 Q37369239-A5851BED-0828-4C00-AD5F-4DBB450F1489 Q38414485-085002DF-0F3D-4BA5-A8A9-9DDF626FBAAB Q38636711-E33F4A24-1DA2-478A-86FB-7F1C60C4E1E2 Q38648615-4A4EA0F3-2E9D-4453-A3DA-9613425D3320 Q38677420-C6420C91-B409-41EF-880D-E522A706E687 Q38710357-7B560133-8B7D-4255-86DA-122BCD92A7E6 Q38783026-DBB6AA5C-7012-4C0B-9172-827CBBECF366 Q38816839-C5037A77-4DF2-4467-8AFC-7CA1EDAD8EB3 Q39085984-05C15F8C-3B45-48B0-9E6A-DB378F6FF024 Q39148284-61930197-6B58-4B14-B242-C4B5FCE9A64A Q46112903-B44B3EF6-271C-4C7E-ADD7-D9739EB82437 Q46884498-510E3BB8-7DD8-47F0-A60F-D951798BE802 Q47225399-1C08BEA5-FC37-4359-8886-FBBC8355FE76 Q48133624-BA3BB840-3909-4021-9185-D0763CB05A4F

P2860

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

http://www.wikidata.org/entity/Q26995499

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Review of immune-related adver ...... imumab: MD Anderson experience

@ast

Review of immune-related adver ...... imumab: MD Anderson experience

@en

Review of immune-related adver ...... imumab: MD Anderson experience

@nl

type

label

Review of immune-related adver ...... imumab: MD Anderson experience

@ast

Review of immune-related adver ...... imumab: MD Anderson experience

@en

Review of immune-related adver ...... imumab: MD Anderson experience

@nl

prefLabel

Review of immune-related adver ...... imumab: MD Anderson experience

@ast

Review of immune-related adver ...... imumab: MD Anderson experience

@en

Review of immune-related adver ...... imumab: MD Anderson experience

@nl

P1433

Q26995499-2B0CD2FD-5FAF-430B-BFC2-076FA07EF8E0

P1476

Q26995499-03D8D725-8348-4A1F-8701-5B4A11A1E5AC

P2093

Q26995499-13E1411A-5DD8-4334-A825-E1023DB7637D

Q26995499-28BC599F-D7F3-41D1-8376-3807BCB5CFC3

Q26995499-627F0FBE-9ED9-4576-B15E-1054DB836B64

Q26995499-702708B4-7C30-411E-B669-B1C3B231A473

Q26995499-8CF4AFD6-1C57-4375-8CE4-BC0BFA5D8052

Q26995499-B0572BC1-F051-4F2A-BBAA-C8C99A6EF7FA

Q26995499-C0131659-0FA0-4632-A7D8-FAC08F2DF09A

Q26995499-C2E51F57-F370-44AA-83CA-B24B8918C72C

Q26995499-F62F4AF9-4EFA-40E3-9FAB-2346CE71E2CB

P2860

Q26995499-05EBA5F7-ABE4-47DA-B355-7ECC7EFE78FF

Q26995499-11B3CC23-BBE7-48C1-BAC4-22F3C709307C

Q26995499-12406B1B-9AA2-441B-8D62-FEE8ADD8B8BC

Q26995499-17119DB9-04E5-4A5C-BD0A-8646B1414A1D

Q26995499-1C8C7716-79C7-4A01-95F5-29820402BC27

Q26995499-1D08BA41-FBE0-4F62-9F2C-086D61D2DE18

Q26995499-20E268C6-46A6-4603-B58D-1DDBE0621FF1

Q26995499-26E7F726-60AD-48FA-9911-721AD7170002

Q26995499-2E0AEA9F-8C3D-4C36-8C6D-AB14B99DE403

Q26995499-3655F2EC-1AE6-4E61-86AC-A4FF5A2D2728

P2888

Q26995499-1FDCB031-62EE-494C-9DDD-5DD05FD9F12C

P304

Q26995499-57B118EB-8FBD-4949-ACBC-5729F06957F2

P31

Q26995499-8FBED99B-03B3-4BA6-A8FE-4BEC9AFAC712

Q26995499-D5766190-8C6D-4C82-8E1C-804AE3E2591A

P3181

Q26995499-C53ABB01-752C-47C2-9424-DBBC97E68BF4

P356

Q26995499-29C920DA-8101-4D46-AA43-23E49FCFD3E9

P407

Q26995499-6B63FC23-2334-400D-B86F-2EB43D32B094

P433

Q26995499-81FB2C7B-6817-4F59-879C-6627DCA64CBC

P478

Q26995499-B3C950BD-B7B0-4E6E-BAAE-0674BFED7904

P577

Q26995499-42B4DE61-129D-4769-A22F-608638B7F88F

Q26995499-CD69F8DB-DBFB-49C0-933B-AD538432BFBF

P6179

Q26995499-BE711561-4F48-493F-B22E-EE7E85B8B161

P698

Q26995499-3C317EEA-7FEA-4756-8A45-8F397EBB7FB3

P921

Q26995499-56188839-A889-45A2-886D-755FF2251952

Q26995499-57C5DD2B-40A6-4E63-B3F4-BA90B1B05105

Q26995499-66E88395-A494-4B30-9981-FEC6406D248B

Q26995499-E53AD495-FD27-41C1-AF51-FC7CF73DEFF5

Q26995499-FAF9A9F5-0927-49FB-B3F9-AB477FF7CD83

P932

Q26995499-FCD7526B-4161-4572-ABBB-AC6B37F1DCE0

P3181

P356

P1433

P1476

Review of immune-related adver ...... imumab: MD Anderson experience

@en

P2093

A Aparicio

http://www.w3.org/2001/XMLSchema#string

A Zurita-Saavedra

http://www.w3.org/2001/XMLSchema#string

C Jimenez

http://www.w3.org/2001/XMLSchema#string

D H Lee

http://www.w3.org/2001/XMLSchema#string

J Gao

http://www.w3.org/2001/XMLSchema#string

M Suarez-Almazor

http://www.w3.org/2001/XMLSchema#string

P Sharma

http://www.w3.org/2001/XMLSchema#string

Q He

http://www.w3.org/2001/XMLSchema#string

S Subudhi

http://www.w3.org/2001/XMLSchema#string

P2860

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Enhancement of antitumor immunity by CTLA-4 blockade

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

Immunologic correlates of the abscopal effect in a patient with melanoma

Ipilimumab and its toxicities: a multidisciplinary approach

P2888

P304

5411-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4245116

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/ONC.2015.5

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1004455849

http://www.w3.org/2001/XMLSchema#string

P698

25659583

http://www.w3.org/2001/XMLSchema#string

P921

prostate cancer

monoclonal antibody

P932

4530091

http://www.w3.org/2001/XMLSchema#string